FDA clears Oridion's capnography device:
This article was originally published in Clinica
Oridion Systems has received US FDA 510(k) clearance to market its device for monitoring non-intubated patients during procedural sedation. The Smart CapnoLine O2 system can help alert caregivers to the earliest possible warning signs of potentially fatal adverse events that can develop during sedation, including apnoea, ventilatory depression and airway obstruction, says the Jerusalem, Israel firm. The device collects breath samples for carbon dioxide analysis from both the nose and mouth, while also supplying oxygen to the patients.
You may also be interested in...
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.